Please login to the form below

Not currently logged in
Email:
Password:

Millennium submits new Velcade applications

Millennium has submitted applications to the US Food and Drug Administration seeking approval of two new indications for its injectable cancer drug Velcade

Millennium has submitted applications to the US Food and Drug Administration (FDA) seeking approval of two new indications for its injectable cancer drug Velcade (bortezomib).

The first application seeks approval of a subcutaneous route of administration for the drug, which is currently approved only as an intravenous therapy. The second seeks approval of Velcade in combination with rituximab for the treatment of relapsed follicular non-Hodgkin lymphoma (NHL).

Velcade, a proteasome inhibitor, was granted accelerated approval in the US in 2003 as a treatment for multiple myeloma. The drug was approved in the US in 2007 as a treatment for patients with mantle cell lymphoma, which is a sub-type of NHL, who have received at least one prior therapy.

The newly submitted supplemental new drug applications (sNDAs) were based on results from clinical trials that were presented at the American Society of Hematology (ASH) annual meeting in late 2010. The subcutaneous pivotal trial findings were also published in the online version of the Lancet Oncology earlier this month.

27th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics